{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"}],"units":"Participants"}],"description":"The percentage of ADA-positive participants after atezolizumab SC formulated with rHuPH20 administration was reported. Participants who received atezolizumab SC formulated with rHuPH20 were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following rHuPH20 exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 t.u. greater than the titer of the baseline sample (treatment-enhanced ADA response). Percentages have been rounded to one decimal place.","groups":[{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG000","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"NUMBER","populationDescription":"Safety-evaluable population included all participants who received at least one dose of atezolizumab SC formulated with rHuPH20. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"From Cycle 1 Day 1 (Cycle length = 21 days) up to treatment discontinuation visit (Up to approximately 20 months)","title":"Part 2: Percentage of Participants With ADAs to rHuPH20 After SC Administration","type":"SECONDARY","unitOfMeasure":"percentage of participants"}